<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We retrospectively evaluated our clinical results of stereotactic radiosurgery (SRS) for <z:hpo ids='HP_0002893'>pituitary adenoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Between 1995 and 2000, 13 patients were treated with SRS for <z:hpo ids='HP_0002893'>pituitary adenoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases, the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> had already been surgically resected </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:mpath ids='MPATH_270'>adenomas</z:mpath> were functional in 5 and non-functional in 8 patients </plain></SENT>
<SENT sid="4" pm="."><plain>The median follow-up period was 30 months </plain></SENT>
<SENT sid="5" pm="."><plain>SRS was performed with the use of a dedicated stereotactic 10-MV linear accelerator (LINAC) </plain></SENT>
<SENT sid="6" pm="."><plain>The median dose to the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> margin was 15 Gy </plain></SENT>
<SENT sid="7" pm="."><plain>The dose to the optic apparatus was limited to less than 8 Gy </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> images of 12 patients revealed <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> CR in one case and PR in 9 cases; in the remaining two patients, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> size decreased by less than 50% </plain></SENT>
<SENT sid="9" pm="."><plain>There was no recognizable regrowth of any of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In two of four GH-secreting <z:mpath ids='MPATH_270'>adenomas</z:mpath>, hormonal overproduction normalized, while the other two showed reduced hormonal production </plain></SENT>
<SENT sid="11" pm="."><plain>One PRL-secreting <z:mpath ids='MPATH_270'>adenoma</z:mpath> did not respond </plain></SENT>
<SENT sid="12" pm="."><plain>Reduction of visual acuity and field was seen in one patient </plain></SENT>
<SENT sid="13" pm="."><plain>This patient also had a <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> </plain></SENT>
<SENT sid="14" pm="."><plain>None of the patients developed brain radionecrosis or radiation-induced <z:mp ids='MP_0003348'>hypopituitarism</z:mp> </plain></SENT>
<SENT sid="15" pm="."><plain>CONCLUSION: Although further studies based on greater numbers of cases and longer follow-up periods are needed, our results suggest that SRS seems to be a safe, effective treatment for <z:hpo ids='HP_0002893'>pituitary adenoma</z:hpo> </plain></SENT>
</text></document>